Nuformix (LON:NFX) Trading 4.8% Higher – Still a Buy?

Nuformix plc (LON:NFX) shares rose 4.8% on Thursday . The stock traded as high as GBX 0.25 and last traded at GBX 0.22. Approximately 20,423,172 shares were traded during mid-day trading, a decline of 39% from the average daily volume of 33,286,676 shares. The stock had previously closed at GBX 0.21.

Nuformix Stock Up 0.4%

The company has a market capitalization of £5.61 million, a P/E ratio of -6.77 and a beta of 1.22. The company has a 50 day simple moving average of GBX 0.26 and a two-hundred day simple moving average of GBX 0.24.

Nuformix (LON:NFX) last issued its quarterly earnings results on Tuesday, January 27th. The company reported GBX (0.04) EPS for the quarter.

Nuformix Company Profile

Nuformix plc operates in the field of pharmaceutical development for treating fibrosis and oncology through drug repurposing in the United Kingdom. It offers NXP001, which has completed Phase 1 for use in oncology supportive care. The company is also developing NXP004, a novel form of Olaparib, which is in the IP generation phase for treating oncology; and NXP002 that is in pre-clinical stage for the treatment of idiopathic pulmonary fibrosis. It also has an option agreement with Oxilio Ltd. for NXP001 for oncology indications.